ArticleCells2021
Cannabidiol Inhibits Tau Aggregation In Vitro.
Article in Cells, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 40 citations in OpenAlex.
- Cannabidiol in Neurology: Current Insights and Translational Perspectives.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Review
- Cannabidiol prevents cognitive and social deficits in a male rat model of Alzheimer's disease through CB1 activation and inflammation modulation.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2025Article
- Investigation of the Effects of Acacetin on Autophagy Pathway and Exosome Release in Amyloid Beta Peptide-Induced Toxicity Models.Molecular neurobiology · 2025Article
- Microtubule-associated protein 4 forms aggregates consisting of helical filaments.Biochemistry and biophysics reports · 2025Article
- Substance Abuse and Cognitive Decline: The Critical Role of Tau Protein as a Potential Biomarker.International journal of molecular sciences · 2025Review
- Cannabidiol and Alzheimer Disease: A Comprehensive Review and In Silico Insights Into Molecular Interactions.The European journal of neuroscience · 2025Review
- Psychoactive substances: novel molecular insights and therapeutic potential for Alzheimer's disease.Translational neurodegeneration · 2025Review
- Cannabidiol as a multifaceted therapeutic agent: mitigating Alzheimer's disease pathology and enhancing cognitive function.Alzheimer's research & therapy · 2025Article
- Cannabidiol in Foods and Food Supplements: Evaluation of Health Risks and Health Claims.Nutrients · 2025Review
- Sensing Biomolecules Associated with Cells' Radiosusceptibility by Advanced Micro- and Nanospectroscopy Techniques.ACS sensors · 2024Article
- Cannabinoids: Potential for Modulation and Enhancement When Combined with Vitamin B12 in Case of Neurodegenerative Disorders.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Endocannabinoid System Changes throughout Life: Implications and Therapeutic Potential for Autism, ADHD, and Alzheimer's Disease.Brain sciences · 2024Review
- Design, synthesis, and evaluation of 2,2'-bipyridyl derivatives as bifunctional agents against Alzheimer's disease.Molecular diversity · 2024Article
- Modulation of Oxidative Stress and Neuroinflammation by Cannabidiol (CBD): Promising Targets for the Treatment of Alzheimer's Disease.Current issues in molecular biology · 2024Review
- Alzheimer's disease, aging, and cannabidiol treatment: a promising path to promote brain health and delay aging.Molecular biology reports · 2024Review
- A systematic study of molecular targets of cannabidiol in Alzheimer's disease.Journal of Alzheimer's disease reports · 2024Review
- Blocking tau transmission by biomimetic graphene nanoparticles.Journal of materials chemistry. B · 2023Article
- Pleiotropic loci for cannabis use disorder severity in multi-ancestry high-risk populations.Molecular and cellular neurosciences · 2023Article
- Cannabidiol's neuroprotective properties and potential treatment of traumatic brain injuries.Frontiers in neurology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A hallmark of Alzheimer's disease (AD) is the accumulation of tau protein in the brain. Compelling evidence indicates that the presence of tau aggregates causes irreversible neuronal destruction, eventually leading to synaptic loss. So far, the inhibition of tau aggregation has been recognized as one of the most effective therapeutic strategies. Cannabidiol (CBD), a major component found in
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.